Market Place
Sourcing Support
Imcheck Shows Promising ICT01 Results In First-Line in AML At ASH
07 Dec 2025 //
GLOBENEWSWIRE
Ascentage Pharma Reveals Positive Results From Lisaftoclax Study
07 Dec 2025 //
GLOBENEWSWIRE
Aptose Spotlights Tuspetinib`s AML Responses at ASH 2025
06 Dec 2025 //
GLOBENEWSWIRE
ImCheck Oral ICT01 Data in First-Line AML at 67th ASH Annual Meet
05 Dec 2025 //
GLOBENEWSWIRE
Kura Oncology Hosts Investor Event On ASH 2025 Data
03 Dec 2025 //
GLOBENEWSWIRE
Amphista Therapeutics Unveils AMX-883 Data At ASH Conference
25 Nov 2025 //
GLOBENEWSWIRE
Menarini Group Unveils Elzonris Data at ASH Annual Meeting
24 Nov 2025 //
PR NEWSWIRE
Gnome Sciences Reveals Cancer Drug`s Potential In Halting ALS
11 Nov 2025 //
GLOBENEWSWIRE
Taran Therapeutics Releases ASH Abstracts On Lenzilumab
04 Nov 2025 //
ACCESSWIRE
ORYZON Reveals Positive Iadademstat Clinical Data At ASH-2025
04 Nov 2025 //
GLOBENEWSWIRE
Sumitomo Pharma America To Unveil New Data at ASH Meeting
03 Nov 2025 //
PR NEWSWIRE
SELLAS Presents Phase 2 Data Of SLS009 With Azacitidine
03 Nov 2025 //
GLOBENEWSWIRE
Aptose Tuspetinib Data In Newly Diagnosed AML Chosen For ASH
03 Nov 2025 //
GLOBENEWSWIRE
AB Science Reports Early Ph1 Data of AB8939 + Venetoclax in AML
16 Oct 2025 //
GLOBENEWSWIRE
AB Science To Host Virtual Conference On AB8939 Phase 1 Study
14 Oct 2025 //
GLOBENEWSWIRE
SELLAS Life Sciences To Showcase SLS009 Survival Benefit
13 Oct 2025 //
GLOBENEWSWIRE
Kura, Kyowa Kirin Dose First Patient in AML Ph 3 Trial
29 Sep 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Publish Ziftomenib Data
25 Sep 2025 //
GLOBENEWSWIRE
Mipletamig Achieves 100% Remission Rate in RAINIER Trial Phase 3
16 Sep 2025 //
PHARMAWEB
AB Science Wins EU Nod for Ph I/II AML Study With AB8939
30 Jul 2025 //
GLOBENEWSWIRE
Abbvie Submitted sNDA for Venetoclax in Untreated CLL
30 Jul 2025 //
PRESS RELEASE
Taiho’s Inqovi Combo sNDA Accepted By US FDA For AML
09 Jul 2025 //
PR NEWSWIRE
Genentech Provides Update on Phase III Verona Study
16 Jun 2025 //
BUSINESSWIRE
AbbVie says blood cancer drug fails late-stage trial
16 Jun 2025 //
REUTERS
Ascentage Pharma presents Lisaftoclax data at ASCO 2025
22 May 2025 //
GLOBENEWSWIRE
SteerLife Announces Its Solvent-Free Melt Fusion Technology
15 May 2025 //
EXPRESSPHARMA
Moleculin Receives EMA Approval to Expand Phase 3 Clinical Trial
12 May 2025 //
GLOBENEWSWIRE
Aptose updates Tuspetinib-based triple drug therapy in AML trial
05 May 2025 //
GLOBENEWSWIRE
AbbVie launches Venetoclax in India for AML and CLL
21 Apr 2025 //
EXPRESSPHARMA
Actinium To Host KOL Call & Provide Pipeline Update
19 Mar 2025 //
PR NEWSWIRE
Actinium Starts Actimab-A Triplet Combo Frontline Trial
11 Mar 2025 //
PR NEWSWIRE
Oryzon Doses First Patient In AML Trial With Iadademstat Combo
13 Jan 2025 //
GLOBENEWSWIRE
Remedy Plan Show Preclinical Data of NAMPT Inhibitor at ASH 2024
10 Dec 2024 //
GLOBENEWSWIRE
Lisaftoclax in Combo Shows Potential in Exposed to Venetoclax
10 Dec 2024 //
PR NEWSWIRE
Fixed-Duration CALQUENCE Plus Venetoclax Superior in Untreated CLL
08 Dec 2024 //
BUSINESSWIRE
ImCheck Receives FDA Fast Track For ICT01 In AML
18 Sep 2024 //
GLOBENEWSWIRE
Delta-Fly Initiates DFP-10917 Phase I/II Combo-study In AML
10 Sep 2024 //
BUSINESSWIRE
SELLAS Life Sciences Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the Second Quarter 2024
08 Aug 2024 //
GLOBENEWSWIRE
AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia
30 Jul 2024 //
PRESS RELEASE
BeiGene To Present BRUKINSA Plus Venetoclax CLL SLL Data
14 Jun 2024 //
BUSINESSWIRE
IMBRUVICA Plus Venetoclax Shows Sustained Benefit In CLL
14 Jun 2024 //
GLOBENEWSWIRE
Delta-Fly Notice to Conduct the Ph I/II of DFP-10917 combined with Venetoclax
08 Apr 2024 //
BUSINESSWIRE
MEI Update from Study Evaluating Voruciclib with Venetoclax in Patients with AML
26 Mar 2024 //
BUSINESSWIRE
Delta-Fly: FDA submission of the protocol of the Phase I/II study of DFP-10917
11 Mar 2024 //
BUSINESSWIRE
Ryvu Announces Dosing of the First Patient in RIVER-81 Phase II Study of RVU120
31 Jan 2024 //
PR NEWSWIRE
Vincerx Announces Compelling Efficacy of Enitociclib with Venetoclax
07 Jan 2024 //
GLOBENEWSWIRE
An Imbruvica combo regimen could have a new future in MCL
13 Dec 2023 //
FIERCE PHARMA
ImmunoGen Presents Findings from Phase 1b/2 Study of Pivekimab Sunirine at ASH
10 Dec 2023 //
BUSINESSWIRE
Syros Announces Initial Data from Phase 2 Trial Evaluating Tamibarotene
06 Dec 2023 //
BUSINESSWIRE
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax
29 Sep 2023 //
PR NEWSWIRE
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter
23 Jun 2023 //
ONCOLIVE
Zanubrutinib Plus Obinutuzumab and Venetoclax Induces High Undetectable MRD
22 Jun 2023 //
ONCLIVE
Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit
22 Jun 2023 //
PRESS RELAESE
Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Clinical Benefit in MCL
19 Jun 2023 //
ONCLIVE
AbbVie`s VENCLYXTO/VENCLEXTA Continues to Show Sustained PFS in CLL
09 Jun 2023 //
PR NEWSWIRE
MEI Pharma Announces Update of PI Study Evaluating CDK9 Inhibitor Voruciclib
23 May 2023 //
BUSINESSWIRE
Ph 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done
15 May 2023 //
BUSINESSWIRE
NICE signs off on AbbVie, J&J`s Imbruvica-Venclyxta combo in CLL
22 Apr 2023 //
FIERCE PHARMA
